Additionally, the PCNA inhibitor T2 amino alcohol (T2AA) synergizes with β-lap to induce increased DNA damage, leading to programmed necrosis and G1 phase cell cycle arrest [21]; nicotinamide phosphoribosyl transferase (NAMPT) inhibition reduces the NAD+ pool in PDA cells, sensitizing them to ROS-mediated cell death by β-lap [25],and co-treatment suppresses SIRT1 activity, increasing the accumulation of acetylated FOXO1 in NSCLC [26]. The gene discussed is NAMPT; the disease is Patent ductus arteriosus.